FileMan FileNo | FileMan Filename | Package |
---|---|---|
165.5 | ONCOLOGY PRIMARY | Oncology |
Package | Total | FileMan Files |
---|---|---|
Oncology | 1 | COMPUTED PRIMARY(#165.59)[.01] |
Field # | Name | Loc | Type | Details |
---|---|---|---|---|
.01 | SITE/GP | 0;1 | POINTER TO SITE-GROUP FOR ONCOLOGY FILE (#164.2) | ************************REQUIRED FIELD************************ SITE-GROUP FOR ONCOLOGY(#164.2)
|
.0101 | PRIMARY SITE/GP | COMPUTED |
|
|
.015 | SELECTED SITES | COMPUTED |
|
|
.017 | SYSTEMS | COMPUTED |
|
|
.02 | PATIENT NAME | 0;2 | POINTER TO ONCOLOGY PATIENT FILE (#160) | ************************REQUIRED FIELD************************ ONCOLOGY PATIENT(#160)
|
.022 | ICDO-SITE | 0;22 | POINTER TO ICDO-SITES FILE (#164.08) | ************************REQUIRED FIELD************************ ICDO-SITES(#164.08)
|
.023 | PRIMARY SITE CODE PREFIX | COMPUTED |
|
|
.025 | PATIENT ID | COMPUTED |
|
|
.03 | REPORTING FACILITY | 0;3 | POINTER TO FACILITY FILE (#160.19) | ************************REQUIRED FIELD************************ FACILITY(#160.19)
|
.04 | CLASS OF CASE | 0;4 | POINTER TO CLASS OF CASE FILE (#165.3) | ************************REQUIRED FIELD************************ CLASS OF CASE(#165.3)
|
.041 | CLASS NO. | COMPUTED |
|
|
.042 | CLASS CATEGORY | 0;20 | SET | ************************REQUIRED FIELD************************
|
.043 | ANALYTIC PRIMARY REQ FOLLOWUP | COMPUTED |
|
|
.05 | ACCESSION NUMBER | 0;5 | FREE TEXT | ************************REQUIRED FIELD************************
|
.06 | SEQUENCE NUMBER | 0;6 | FREE TEXT |
|
.061 | ACC/SEQ NUMBER | COMPUTED |
|
|
.07 | ACCESSION YEAR | 0;7 | FREE TEXT | ************************REQUIRED FIELD************************
|
.08 | MEDICAL RECORD NUMBER | COMPUTED |
|
|
.09 | SOCIAL SECURITY NUMBER | COMPUTED |
|
|
.091 | STATUS | COMPUTED |
|
|
.093 | PLACE OF BIRTH (STATE) | COMPUTED |
|
|
.1 | SEX | COMPUTED |
|
|
.115 | STATE | COMPUTED |
|
|
.1157 | ST-COUNTY | COMPUTED |
|
|
.117 | COUNTY | COMPUTED |
|
|
.12 | RACE | COMPUTED |
|
|
.13 | RACE-SEX | COMPUTED |
|
|
.14 | SEX-RACE | COMPUTED |
|
|
1 | DATE OF INPATIENT ADMISSION | 0;8 | DATE |
|
1.1 | DATE OF INPATIENT DISCHARGE | 0;9 | DATE |
|
1.2 | TYPE OF REPORTING SOURCE | 0;10 | POINTER TO TYPE OF REPORTING SOURCE FILE (#168) | TYPE OF REPORTING SOURCE(#168)
|
2 | PRIMARY SURGEON | 0;11 | POINTER TO ONCOLOGY CONTACT FILE (#165) | ONCOLOGY CONTACT(#165)
|
2.1 | FOLLOWING PHYSICIAN | 0;12 | POINTER TO ONCOLOGY CONTACT FILE (#165) | ONCOLOGY CONTACT(#165)
|
2.2 | MANAGING PHYSICIAN | 0;13 | POINTER TO ONCOLOGY CONTACT FILE (#165) | ONCOLOGY CONTACT(#165)
|
2.3 | PHYSICIAN #3 | 0;14 | POINTER TO ONCOLOGY CONTACT FILE (#165) | ONCOLOGY CONTACT(#165)
|
2.4 | PHYSICIAN #4 | 0;15 | POINTER TO ONCOLOGY CONTACT FILE (#165) | ONCOLOGY CONTACT(#165)
|
3 | DATE DX | 0;16 | DATE | ************************REQUIRED FIELD************************
|
3.1 | DIAGNOSIS EPISODE CARE | COMPUTED |
|
|
3.5 | YEAR DX | COMPUTED DATE |
|
|
4 | AGE AT DX | COMPUTED |
|
|
4.1 | DX AGE-GP | COMPUTED |
|
|
5 | DX FACILITY | 0;17 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
|
6 | FACILITY REFERRED FROM | 0;18 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
|
7 | FACILITY REFERRED TO | 0;19 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
|
8 | PATIENT ADDRESS AT DX | 1;1 | FREE TEXT |
|
8.1 | CITY/TOWN AT DX | 1;12 | FREE TEXT |
|
8.2 | PATIENT ADDRESS AT DX - SUPP | 1;13 | FREE TEXT |
|
9 | POSTAL CODE AT DX | 1;2 | FREE TEXT |
|
10 | COUNTY AT DX | 1;3 | FREE TEXT |
|
11 | MARITAL STATUS AT DX | 1;5 | SET |
|
12 | PALLIATIVE CARE | 3.1;26 | SET |
|
13 | PALLIATIVE CARE @FAC | 3.1;27 | SET |
|
14 | READMISSION W/I 30 DAYS/SURG | 3.1;28 | SET |
|
15 | SYSTEMIC/SURGERY SEQUENCE | 3.1;39 | SET |
|
16 | STATE AT DX | 1;4 | POINTER TO STATE FILE (#5) | STATE(#5)
|
17 | SUSPENSE DATE | 1;10 | DATE |
|
18 | PRIMARY PAYER AT DX | 1;11 | POINTER TO PRIMARY PAYER AT DIAGNOSIS FILE (#160.3) | PRIMARY PAYER AT DIAGNOSIS(#160.3)
|
19 | STAGED BY (CLINICAL STAGE) | 3;32 | POINTER TO ONCOLOGY STAGED BY CODES FILE (#165.7) | ONCOLOGY STAGED BY CODES(#165.7)
|
20 | PRIMARY SITE | 2;1 | POINTER TO ICDO TOPOGRAPHY FILE (#164) | ************************REQUIRED FIELD************************ ICDO TOPOGRAPHY(#164)
|
20.1 | PRIMARY SITE CODE | COMPUTED |
|
|
21 | CASEFINDING SOURCE | 1;6 | POINTER TO CASEFINDING SOURCE FILE (#166) | ************************REQUIRED FIELD************************ CASEFINDING SOURCE(#166)
|
21.5 | INFRA/SUPRA | 2;7 | SET | ************************REQUIRED FIELD************************
|
21.51 | IRIS/CILIARY BODY | 2;22 | SET |
|
21.52 | UPPER/LOWER | 24;4 | SET |
|
22 | HISTOLOGY (ICD-O-2) | 2;3 | POINTER TO ICD-O-2 MORPHOLOGY FILE (#164.1) | ICD-O-2 MORPHOLOGY(#164.1)
|
22.1 | ICDO HISTOLOGY-CODE | COMPUTED |
|
|
22.2 | PAPILLARY/FOLLICULAR | 2;4 | SET |
|
22.3 | HISTOLOGY (ICD-O-3) | 2.2;3 | POINTER TO ICD-O-3 MORPHOLOGY FILE (#169.3) | ICD-O-3 MORPHOLOGY(#169.3)
|
22.4 | BEHAVIOR CODE | COMPUTED |
|
|
23 | RECONSTRUCTION/RESTORATION | 3;33 | FREE TEXT |
|
24 | GRADE/DIFFERENTIATION | 2;5 | POINTER TO GRADE FILE (#164.43) | GRADE(#164.43)
|
24.1 | GRADE PATH SYSTEM | 2.3;1 | SET |
|
24.2 | GRADE PATH VALUE | 2.3;2 | SET |
|
24.3 | GRADE CLINICAL | 2.3;12 | FREE TEXT |
|
24.4 | GRADE PATHOLOGICAL | 2.3;13 | FREE TEXT |
|
24.5 | GRADE POST THERAPY PATH (YP) | 2.3;14 | FREE TEXT |
|
24.6 | GRADE POST THERAPY CLIN (YC) | 2.3;15 | FREE TEXT |
|
25 | TNM FORM ASSIGNED | 7;7 | FREE TEXT |
|
25.1 | TUMOR MARKER 1 | 24;2 | POINTER TO TUMOR MARKERS FILE (#164.15) | TUMOR MARKERS(#164.15)
|
25.2 | TUMOR MARKER 2 | 24;3 | POINTER TO TUMOR MARKERS FILE (#164.15) | TUMOR MARKERS(#164.15)
|
25.3 | TUMOR MARKER 3 | 24;7 | POINTER TO TUMOR MARKERS FILE (#164.15) | TUMOR MARKERS(#164.15)
|
26 | DIAGNOSTIC CONFIRMATION | 2;6 | SET |
|
27 | HISTO-MORPHOLOGY | COMPUTED |
|
|
28 | LATERALITY | 2;8 | SET |
|
29 | TUMOR SIZE | 2;9 | NUMBER |
|
29.1 | TUMOR SIZE/EXT EVAL (CS) | CS;1 | FREE TEXT |
|
29.2 | TUMOR SIZE (CS) | CS1;10 | FREE TEXT |
|
29.3 | TUMOR SIZE SUMMARY | 2.1;20 | NUMBER |
|
29.4 | TUMOR SIZE CLINICAL | 2.1;21 | NUMBER |
|
29.5 | TUMOR SIZE PATHOLOGIC | 2.1;22 | NUMBER |
|
29.9 | EXTENSION LIST USED | COMPUTED |
|
|
30 | EXTENSION | 2;10 | NUMBER |
|
30.1 | PATHOLOGIC EXTENSION | 2.2;2 | NUMBER |
|
30.2 | EXTENSION (CS) | CS;11 | FREE TEXT |
|
30.5 | PERIPHERAL BLOOD INVOLVEMENT | 24;5 | SET |
|
30.9 | LYMPH NODE LIST USED | COMPUTED |
|
|
31 | LYMPH NODES | 2;11 | NUMBER |
|
31.1 | LYMPH NODES (CS) | CS;12 | FREE TEXT |
|
32 | REGIONAL LYMPH NODES POSITIVE | 2;12 | NUMBER |
|
32.1 | LYMPH NODES EVAL (CS) | CS;2 | FREE TEXT |
|
33 | REGIONAL LYMPH NODES EXAMINED | 2;13 | NUMBER |
|
33.1 | #NODES EXAMINED | COMPUTED |
|
|
34 | SITE OF DISTANT METASTASIS #1 | 2;14 | SET |
|
34.1 | SITE OF DISTANT METASTASIS #2 | 2;15 | SET |
|
34.2 | SITE OF DISTANT METASTASIS #3 | 2;16 | SET |
|
34.3 | METS AT DX (CS) | CS;3 | FREE TEXT |
|
34.31 | METS AT DX-BONE | CS1;20 | SET |
|
34.32 | METS AT DX-BRAIN | CS1;21 | SET |
|
34.33 | METS AT DX-LIVER | CS1;22 | SET |
|
34.34 | METS AT DX-LUNG | CS1;23 | SET |
|
34.35 | METS AT DX-DISTANT LN | CS1;24 | SET |
|
34.36 | METS AT DX-OTHER | CS1;25 | SET |
|
34.4 | METS EVAL (CS) | CS;4 | FREE TEXT |
|
35 | SEER SUMMARY STAGE 2000 | 2;17 | SET |
|
35.1 | SEER SUMMARY STAGE ABBREVIATED | COMPUTED |
|
|
36 | AJCC STAGING BASIS | 2;18 | SET |
|
37 | TNM CLINICAL | COMPUTED |
|
|
37.1 | CLINICAL T | 2;25 | FREE TEXT |
|
37.2 | CLINICAL N | 2;26 | FREE TEXT |
|
37.3 | CLINICAL M | 2;27 | FREE TEXT |
|
37.9 | AUTOMATIC STAGING OVERRIDDEN | 24;1 | SET |
|
38 | STAGE GROUP CLINICAL | 2;20 | FREE TEXT |
|
38.1 | GP-I AJCC SUMMARY STAGE | COMPUTED |
|
|
38.2 | GP-II AJCC SUMMARY STAGE | COMPUTED |
|
|
38.3 | GP-III AJCC SUMMARY STAGE | COMPUTED |
|
|
38.4 | GP-IV AJCC SUMMARY STAGE | COMPUTED |
|
|
38.5 | STAGE GROUPING-AJCC | 2;28 | SET |
|
39 | OTHER STAGING SYSTEM | 2;21 | POINTER TO OTHER STAGING FOR ONCOLOGY FILE (#164.3) | OTHER STAGING FOR ONCOLOGY(#164.3)
|
40 | STAGE GROUP BEST | COMPUTED |
|
|
40.1 | TNM BEST | COMPUTED |
|
|
40.2 | STAGED BY | COMPUTED |
|
|
41 | ASSOCIATED WITH HIV | 2;23 | SET |
|
42 | TREATMENT ABBREVIATED | COMPUTED |
|
|
43 | TREATMENT | COMPUTED |
|
|
44 | TNM FORM COMPLETED | 7;14 | FREE TEXT |
|
44.1 | SSF1 | CS;5 | FREE TEXT |
|
44.101 | SSF10 | CS2;4 | FREE TEXT |
|
44.11 | SSF11 | CS2;5 | FREE TEXT |
|
44.12 | SSF12 | CS2;6 | FREE TEXT |
|
44.13 | SSF13 | CS2;7 | FREE TEXT |
|
44.14 | SSF14 | CS2;8 | FREE TEXT |
|
44.15 | SSF15 | CS2;9 | FREE TEXT |
|
44.16 | SSF16 | CS2;10 | FREE TEXT |
|
44.17 | SSF17 | CS2;11 | FREE TEXT |
|
44.18 | SSF18 | CS2;12 | FREE TEXT |
|
44.19 | SSF19 | CS2;13 | FREE TEXT |
|
44.2 | SSF2 | CS;6 | FREE TEXT |
|
44.201 | SSF20 | CS2;14 | FREE TEXT |
|
44.21 | SSF21 | CS2;15 | FREE TEXT |
|
44.22 | SSF22 | CS2;16 | FREE TEXT |
|
44.23 | SSF23 | CS2;17 | FREE TEXT |
|
44.24 | SSF24 | CS2;18 | FREE TEXT |
|
44.25 | SSF25 | CS2;19 | FREE TEXT |
|
44.3 | SSF3 | CS;7 | FREE TEXT |
|
44.4 | SSF4 | CS;8 | FREE TEXT |
|
44.5 | SSF5 | CS;9 | FREE TEXT |
|
44.6 | SSF6 | CS;10 | FREE TEXT |
|
44.7 | SSF7 | CS2;1 | FREE TEXT |
|
44.8 | SSF8 | CS2;2 | FREE TEXT |
|
44.9 | SSF9 | CS2;3 | FREE TEXT |
|
45 | PERFORMANCE STATUS | 2;24 | SET |
|
46 | CAP PROTOCOL REVIEW | 7;19 | SET |
|
47 | CAP TEXT | 7;20 | FREE TEXT |
|
48 | OTHER PRIMARY SITES | COMPUTED |
|
|
49 | FIRST COURSE OF TREATMENT DATE | COMPUTED |
|
|
49.1 | FIRST TREATMENT DT-DATE DX | COMPUTED |
|
|
49.9 | DATE INITIAL RX SEER | COMPUTED |
|
|
50 | MOST DEFINITIVE SURG DATE | 3;1 | DATE |
|
50.1 | SURGERY HOSPITAL | 3;2 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
|
50.2 | SURGERY OF PRIMARY @FAC (R) | 3.1;7 | FREE TEXT |
|
50.3 | MOST DEFINITIVE SURG @FAC DATE | 3.1;8 | DATE |
|
51 | DATE RADIATION STARTED | 3;4 | DATE |
|
51.1 | RADIATION HOSPITAL | 3;5 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
|
51.2 | RADIATION | 3;6 | SET |
|
51.3 | RADIATION/SURGERY SEQUENCE | 3;7 | SET |
|
51.4 | RADIATION @FACILITY | 3.1;12 | SET |
|
51.5 | RADIATION @FACILITY DATE | 3.1;13 | DATE |
|
52 | RADIATION THERAPY TO CNS DATE | 3;8 | DATE |
|
52.1 | RADIATION THERAPY TO CNS HOSP | 3;9 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
|
52.2 | RADIATION THERAPY TO CNS | 3;10 | SET |
|
53 | CHEMOTHERAPY DATE | 3;11 | DATE |
|
53.1 | CHEMOTHERAPY HOSPITAL | 3;12 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
|
53.2 | CHEMOTHERAPY | 3;13 | SET |
|
53.3 | CHEMOTHERAPY @FAC | 3.1;14 | SET |
|
53.4 | CHEMOTHERAPY @FAC DATE | 3.1;15 | DATE |
|
54 | HORMONE THERAPY DATE | 3;14 | DATE |
|
54.1 | HORMONE THERAPY HOSPITAL | 3;15 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
|
54.2 | HORMONE THERAPY | 3;16 | SET |
|
54.3 | HORMONE THERAPY @FAC | 3.1;16 | SET |
|
54.4 | HORMONE THERAPY @FAC DATE | 3.1;17 | DATE |
|
55 | IMMUNOTHERAPY DATE | 3;17 | DATE |
|
55.1 | IMMUNOTHERAPY HOSPITAL | 3;18 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
|
55.2 | IMMUNOTHERAPY | 3;19 | SET |
|
55.3 | IMMUNOTHERAPY @FAC | 3.1;18 | SET |
|
55.4 | IMMUNOTHERAPY @FAC DATE | 3.1;19 | DATE |
|
56 | NUMBER OF TXS TO THIS VOLUME | 3;20 | NUMBER |
|
57 | OTHER TREATMENT START DATE | 3;23 | DATE |
|
57.1 | OTHER TREATMENT HOSPITAL | 3;24 | POINTER TO FACILITY FILE (#160.19) | FACILITY(#160.19)
|
57.2 | OTHER TREATMENT | 3;25 | SET |
|
57.3 | OTHER TREATMENT @FAC | 3.1;20 | SET |
|
57.4 | OTHER TREATMENT @FACILITY DATE | 3.1;21 | DATE |
|
58 | REASON NO SURGERY OF PRIMARY | 3;26 | SET |
|
58.1 | SURGICAL DX/STAGING PROC | 3;27 | FREE TEXT |
|
58.2 | SURGERY OF PRIMARY (R) | 3;38 | NUMBER |
|
58.3 | SURGICAL DX/STAGING PROC DATE | 3;31 | DATE |
|
58.4 | SURG DX/STAGING PROC @FAC | 3.1;5 | FREE TEXT |
|
58.5 | SURG DX/STAGING PROC @FAC DATE | 3.1;6 | DATE |
|
58.6 | SURGERY OF PRIMARY (F) | 3.1;29 | FREE TEXT |
|
58.7 | SURGERY OF PRIMARY @FAC (F) | 3.1;30 | FREE TEXT |
|
58.8 | RX HOSP--SURG PRIM SITE 2023 | 3.2;8 | FREE TEXT |
|
58.9 | RX SUMM--SURG PRIM SITE 2023 | 3.2;9 | FREE TEXT |
|
59 | SURGICAL MARGINS | 3;28 | SET |
|
60 | SUBSEQUENT COURSE OF TREATMENT | 4;0 | DATE Multiple #165.51 | 165.51
|
61 | PID# | COMPUTED |
|
|
62 | QA SELECTED | 7;4 | SET |
|
63 | QA REVIEW | 7;8 | SET |
|
64 | QA DATE | 7;9 | DATE |
|
64.1 | QA REVIEWER | 7;18 | POINTER TO NEW PERSON FILE (#200) | NEW PERSON(#200)
|
64.2 | QA FINDINGS | 28;0 | WORD-PROCESSING #165.54 |
|
65 | PHYSICIAN'S STAGE | 7;10 | FREE TEXT |
|
66 | PHYSICIAN STAGING | 7;11 | POINTER TO ONCOLOGY CONTACT FILE (#165) | ONCOLOGY CONTACT(#165)
|
67 | ACOS # | COMPUTED |
|
|
68 | STATE HOSPITAL # | COMPUTED |
|
|
69 | MULTIPLE TUMORS | 2;31 | NUMBER |
|
69.1 | FAMILY HISTORY | 2;32 | SET |
|
69.2 | DIFFUSE RETINAL INVOLVEMENT | 3;30 | SET |
|
69.3 | MULTIMODALITY THERAPY (CLIN) | 7;16 | SET |
|
69.4 | MULTIMODALITY THERAPY | 7;17 | SET |
|
70 | DATE OF FIRST RECURRENCE | 5;1 | DATE |
|
71 | TYPE OF FIRST RECURRENCE | 5;2 | POINTER TO TYPE OF RECURRENCE FILE (#160.12) | TYPE OF RECURRENCE(#160.12)
|
71.1 | DISTANT SITE 1 | 5;3 | SET |
|
71.2 | DISTANT SITE 2 | 5;4 | SET |
|
71.3 | DISTANT SITE 3 | 5;5 | SET |
|
71.4 | OTHER TYPE OF FIRST RECURRENCE | 5;6 | POINTER TO TYPE OF RECURRENCE FILE (#160.12) | TYPE OF RECURRENCE(#160.12)
|
72 | SUBSEQUENT RECURRENCES | 23;0 | DATE Multiple #165.572 | 165.572
|
73 | TUMOR STATUS | TS;0 | DATE Multiple #165.573 | 165.573
|
74 | SURGICAL APPROACH (R) | 3;34 | NUMBER |
|
75 | REASON FOR NO RADIATION | 3;35 | SET |
|
76 | REASON FOR NO CHEMOTHERAPY | 3;36 | SET |
|
77 | REASON FOR NO HORMONE THERAPY | 3;37 | SET |
|
78 | CONVERTED | 24;6 | SET |
|
78.1 | CONVERTED STAGED BY FIELDS | 25;19 | SET |
|
78.2 | CONVERTED TNM FIELDS | 25;20 | SET |
|
79 | SCREENING DATE | 0;24 | DATE |
|
80 | RADIATION TREATMENT | 6;0 | Multiple #165.52 | 165.52
|
81 | COMPLETED BY | 7;12 | FREE TEXT |
|
82 | REVIEWED BY CANCER COMMITTEE | 7;13 | FREE TEXT |
|
83 | AFIP/JPC SUBMISSION | 0;21 | SET |
|
84 | PCE INDICATOR | 7;15 | SET |
|
85 | PATHOLOGIC T | 2.1;1 | FREE TEXT |
|
86 | PATHOLOGIC N | 2.1;2 | FREE TEXT |
|
87 | PATHOLOGIC M | 2.1;3 | FREE TEXT |
|
88 | STAGE GROUP PATHOLOGIC | 2.1;4 | FREE TEXT |
|
89 | STAGED BY (PATHOLOGIC STAGE) | 2.1;5 | POINTER TO ONCOLOGY STAGED BY CODES FILE (#165.7) | ONCOLOGY STAGED BY CODES(#165.7)
|
89.1 | TNM PATHOLOGIC | COMPUTED |
|
|
90 | DATE CASE COMPLETED | 7;1 | DATE |
|
91 | ABSTRACT STATUS | 7;2 | SET |
|
92 | ABSTRACTED BY | 7;3 | POINTER TO NEW PERSON FILE (#200) | ************************REQUIRED FIELD************************ NEW PERSON(#200)
|
93 | OTHER T | 2.1;6 | FREE TEXT |
|
94 | REPORTING DATE | 7;5 | DATE |
|
95 | LAST TUMOR STATUS | 7;6 | POINTER TO PRIMARY CANCER STATUS CODE FILE (#164.42) | PRIMARY CANCER STATUS CODE(#164.42)
|
95.1 | V STATUS/LAST TUMOR STATUS | COMPUTED |
|
|
96 | PSA DATE | PRO2;50 | FREE TEXT |
|
97 | ABSTRACT INCOMPLETE | BOOLEAN COMPUTED |
|
|
98 | OTHER N | 2.1;7 | FREE TEXT |
|
99 | OTHER M | 2.1;8 | FREE TEXT |
|
100 | TEXT-PRIMARY SITE TITLE | 8;1 | FREE TEXT |
|
101 | TEXT-HISTOLOGY TITLE | 8;2 | FREE TEXT |
|
102 | DRE +/- | 24;10 | SET |
|
103 | TEXT-DX PROC-OP | 9;0 | WORD-PROCESSING #165.5103 |
|
104 | TEXT-DX PROC-PE | 10;0 | WORD-PROCESSING #165.5104 |
|
105 | TEXT-DX PROC-X-RAY/SCAN | 11;0 | WORD-PROCESSING #165.5105 |
|
106 | TEXT-DX PROC-SCOPES | 12;0 | WORD-PROCESSING #165.5106 |
|
107 | TEXT-DX PROC-PATH | 13;0 | WORD-PROCESSING #165.5107 |
|
108 | RX TEXT-SURGERY | 14;0 | WORD-PROCESSING #165.5108 |
|
109 | RX TEXT-RADIATION | 15;0 | WORD-PROCESSING #165.5109 |
|
110 | RX TEXT-RADIATION OTHER | 16;0 | WORD-PROCESSING #165.53 |
|
111 | RX TEXT-CHEMO | 17;0 | WORD-PROCESSING #165.5111 |
|
112 | RX TEXT-HORMONE | 18;0 | WORD-PROCESSING #165.5112 |
|
113 | TEXT-REMARKS | 19;0 | WORD-PROCESSING #165.5113 |
|
114 | RX TEXT-BRM | 20;0 | WORD-PROCESSING #165.5114 |
|
115 | RX TEXT-OTHER | 21;0 | WORD-PROCESSING #165.5115 |
|
116 | TEXT-DX PROC-LAB TESTS | 22;0 | WORD-PROCESSING #165.5116 |
|
117 | OTHER STAGE GROUP | 2.1;9 | FREE TEXT |
|
118 | STAGED BY (OTHER STAGE) | 2.1;10 | SET |
|
119 | SCREENING RESULT | 0;25 | SET |
|
120 | PRESENTATION AT CANCER CONF | 0;26 | SET |
|
121 | DATE OF CANCER CONF | 0;27 | DATE |
|
122 | REFERRAL TO SUPPORT SERVICES | 0;28 | SET |
|
123 | INPATIENT/OUTPATIENT STATUS | 0;23 | SET |
|
124 | DATE OF NO TREATMENT | 2.1;11 | DATE |
|
125 | RADIATION TREATMENT VOLUME | 3;21 | POINTER TO RADIATION TREATMENT VOLUME FILE (#164.7) | RADIATION TREATMENT VOLUME(#164.7)
|
126 | LOCATION OF RADIATION TX | 3;22 | SET |
|
127 | INTENT OF RADIATION | 3;29 | SET |
|
128 | RADIATION COMPLETION STATUS | 3;39 | POINTER TO RADIATION COMPLETION STATUS FILE (#164.8) | RADIATION COMPLETION STATUS(#164.8)
|
129 | RADIATION AUXILIARY VOLUME | 3.1;1 | POINTER TO RADIATION TREATMENT VOLUME FILE (#164.7) | RADIATION TREATMENT VOLUME(#164.7)
|
130 | RADIATION AUXILIARY DATE | 3.1;2 | DATE |
|
131 | RADIATION AUXILIARY TEXT | 15.1;0 | WORD-PROCESSING #165.5131 |
|
132 | RADIATION LOCAL CONTROL STATUS | 3.1;3 | SET |
|
133 | YEAR PUT ON PROTOCOL | 3.1;4 | FREE TEXT |
|
134 | CLINICAL RISK FACTORS | 2.1;12 | SET |
|
135 | PATHOLOGIC RISK FACTORS | 2.1;13 | SET |
|
136 | SERUM TUMOR MARKERS | 24;8 | SET |
|
137 | DATE OF 1ST POSITIVE BIOPSY | 2.2;1 | DATE |
|
138 | SCOPE OF LN SURGERY (R) | 3;40 | NUMBER |
|
138.1 | SCOPE OF LN SURGERY @FAC (R) | 3.1;9 | FREE TEXT |
|
138.2 | SCOPE OF LN SURGERY DATE | 3.1;22 | DATE |
|
138.3 | SCOPE OF LN SURGERY @FAC DATE | 3.1;23 | DATE |
|
138.4 | SCOPE OF LN SURGERY (F) | 3.1;31 | SET |
|
138.5 | SCOPE OF LN SURGERY @FAC (F) | 3.1;32 | SET |
|
139 | SURG PROC/OTHER SITE (R) | 3;41 | NUMBER |
|
139.1 | SURG PROC/OTHER SITE @FAC (R) | 3.1;10 | FREE TEXT |
|
139.2 | SURG PROC/OTHER SITE DATE | 3.1;24 | DATE |
|
139.3 | SURG PROC/OTHER SITE @FAC DATE | 3.1;25 | DATE |
|
139.4 | SURG PROC/OTHER SITE (F) | 3.1;33 | SET |
|
139.5 | SURG PROC/OTHER SITE @FAC (F) | 3.1;34 | SET |
|
139.6 | METS SITE RESECTED | 3.1;41 | SET |
|
139.7 | METS SITE RESECTED DATE | 3.2;1 | DATE |
|
140 | NUMBER OF LN REMOVED (R) | 3;42 | NUMBER |
|
140.1 | NUMBER OF LN REMOVED @FAC (R) | 3.1;11 | FREE TEXT |
|
141 | BIOPSY PROCEDURE | 2.1;14 | NUMBER |
|
142 | GUIDANCE | 2.1;15 | NUMBER |
|
143 | PALPABILITY OF PRIMARY | 2.1;16 | SET |
|
144 | FIRST DETECTED BY | 2.1;17 | SET |
|
145 | APPROACH FOR BIOPSY OF PRIMARY | 2.1;18 | SET |
|
146 | BIOPSY OF OTHER THAN PRIMARY | 2.1;19 | SET |
|
147 | CENSUS TRACT | 0;29 | FREE TEXT |
|
148 | OTHER CANCER | 0;30 | SET |
|
148.1 | CANCER #1 | 0;31 | POINTER TO SITE-GROUP FOR ONCOLOGY FILE (#164.2) | SITE-GROUP FOR ONCOLOGY(#164.2)
|
148.2 | CANCER #2 | 0;32 | POINTER TO SITE-GROUP FOR ONCOLOGY FILE (#164.2) | SITE-GROUP FOR ONCOLOGY(#164.2)
|
148.3 | CANCER #3 | 0;33 | POINTER TO SITE-GROUP FOR ONCOLOGY FILE (#164.2) | SITE-GROUP FOR ONCOLOGY(#164.2)
|
148.4 | CANCER #4 | 0;34 | POINTER TO SITE-GROUP FOR ONCOLOGY FILE (#164.2) | SITE-GROUP FOR ONCOLOGY(#164.2)
|
149 | LYMPH-VASCULAR INVASION (L) | 2;19 | SET |
|
150 | FOLLOW-UP HISTORY | COMPUTED |
|
|
151 | VENOUS INVASION (V) | 2;29 | SET |
|
152 | DATE SYSTEMIC THERAPY STARTED | COMPUTED |
|
|
153 | HEMA TRANS/ENDOCRINE PROC | 3.1;36 | POINTER TO HEMATOLOGIC TRANSPLANT/ENDOCRINE PROCEDURES FILE (#167) | HEMATOLOGIC TRANSPLANT/ENDOCRINE PROCEDURES(#167)
|
153.1 | HEMA TRANS/ENDOCRINE PROC DATE | 3.1;35 | DATE |
|
153.2 | HEMA TRANS/ENDOCRINE PROC @FAC | 3.2;2 | POINTER TO HEMATOLOGIC TRANSPLANT/ENDOCRINE PROCEDURES FILE (#167) | HEMATOLOGIC TRANSPLANT/ENDOCRINE PROCEDURES(#167)
|
153.3 | HEMA TRANS/ENDOCRINE PR@FAC DT | 3.2;3 | DATE |
|
154 | PAIN ASSESSMENT | 3.1;37 | SET |
|
155 | DATE OF FIRST CONTACT | 0;35 | DATE | ************************REQUIRED FIELD************************
|
156 | DRE DATE | 24;11 | FREE TEXT |
|
157 | ELAPSED DAYS TO COMPLETION | COMPUTED |
|
|
157.1 | ELAPSED MONTHS TO COMPLETION | COMPUTED |
|
|
159 | AMBIGUOUS TERMINOLOGY DX | 24;12 | SET |
|
160 | DERIVED AJCC-6 T | CS1;1 | FREE TEXT |
|
160.7 | DERIVED AJCC-7 T | CS1;13 | FREE TEXT |
|
161 | DERIVED AJCC-6 T DESCRIPTOR | CS1;2 | SET |
|
161.7 | DERIVED AJCC-7 T DESCRIPTOR | CS1;14 | SET |
|
162 | DERIVED AJCC-6 N | CS1;3 | FREE TEXT |
|
162.7 | DERIVED AJCC-7 N | CS1;15 | FREE TEXT |
|
163 | DERIVED AJCC-6 N DESCRIPTOR | CS1;4 | SET |
|
163.7 | DERIVED AJCC-7 N DESCRIPTOR | CS1;16 | SET |
|
164 | DERIVED AJCC-6 M | CS1;5 | FREE TEXT |
|
164.7 | DERIVED AJCC-7 M | CS1;17 | FREE TEXT |
|
165 | DERIVED AJCC-6 M DESCRIPTOR | CS1;6 | SET |
|
165.7 | DERIVED AJCC-7 M DESCRIPTOR | CS1;18 | SET |
|
166 | DERIVED AJCC-6 STAGE GROUP | CS1;7 | FREE TEXT |
|
166.7 | DERIVED AJCC-7 STAGE GROUP | CS1;19 | FREE TEXT |
|
167 | DERIVED SS1977 | CS1;8 | SET |
|
168 | DERIVED SS2000 | CS1;9 | SET |
|
169 | CS VERSION DERIVED | CS1;11 | FREE TEXT |
|
169.1 | CS VERSION INPUT ORIGINAL | CS1;12 | FREE TEXT |
|
170 | DATE FIRST SURGICAL PROCEDURE | 3.1;38 | DATE |
|
171 | DATE OF FIRST SYMPTOMS | 2.2;4 | FREE TEXT |
|
172 | DATE START OF WORKUP ORDERED | 2.2;5 | FREE TEXT |
|
173 | DATE WORKUP STARTED | 2.2;6 | FREE TEXT |
|
174 | BLOOD IN SPUTUM PER PT | 2.2;7 | SET |
|
174.1 | DATE OF BLOOD IN SPUTUM PER PT | 2.2;18 | FREE TEXT |
|
175 | CHEST X-RAY | 2.2;8 | SET |
|
175.1 | DATE OF CHEST X-RAY | 2.2;19 | FREE TEXT |
|
176 | CT SCAN | 2.2;9 | SET |
|
176.1 | DATE OF CT SCAN | 2.2;20 | FREE TEXT |
|
177 | BRONCHOSCOPY | 2.2;10 | SET |
|
177.1 | DATE OF BRONCHOSCOPY | 2.2;21 | FREE TEXT |
|
178 | MEDIASTINOSCOPY | 2.2;11 | SET |
|
178.1 | DATE OF MEDIASTINOSCOPY | 2.2;22 | FREE TEXT |
|
179 | PET SCAN | 2.2;12 | SET |
|
179.1 | DATE OF PET SCAN | 2.2;23 | FREE TEXT |
|
180 | CHANGE IN BOWEL HABITS PER PT | 2.2;13 | SET |
|
180.1 | DATE OF CHANGE IN BOWEL HABITS | 2.2;24 | FREE TEXT |
|
181 | FECAL OCCULT BLOOD TEST (FOBT) | 2.2;14 | SET |
|
181.1 | DATE OF FOBT | 2.2;25 | FREE TEXT |
|
182 | BARIUM ENEMA | 2.2;15 | SET |
|
182.1 | DATE OF BARIUM ENEMA | 2.2;27 | FREE TEXT |
|
183 | SIGMOIDOSCOPY | 2.2;16 | SET |
|
183.1 | DATE OF SIGMOIDOSCOPY | 2.2;28 | FREE TEXT |
|
184 | CT OF ABDOMEN/PELVIS | 2.2;17 | SET |
|
184.1 | DATE OF CT OF ABDOMEN/PELVIS | 2.2;31 | FREE TEXT |
|
185 | COLONOSCOPY | 2.2;29 | SET |
|
185.1 | DATE OF COLONOSCOPY | 2.2;30 | FREE TEXT |
|
186 | DYSPNEA | 2.2;32 | SET |
|
186.1 | DATE OF DYSPNEA | 2.2;33 | FREE TEXT |
|
187 | INCREASED COUGH | 2.2;34 | SET |
|
187.1 | DATE OF INCREASED COUGH | 2.2;35 | FREE TEXT |
|
188 | FEVER | 2.2;36 | SET |
|
188.1 | DATE OF FEVER | 2.2;37 | FREE TEXT |
|
189 | NIGHT SWEATS | 2.2;38 | SET |
|
189.1 | DATE OF NIGHT SWEATS | 2.2;39 | FREE TEXT |
|
190 | WEIGHT LOSS PER PT | 2.2;40 | SET |
|
191 | ULCERATIVE COLITIS (UC) | 2.2;41 | SET |
|
192 | SPORADIC POLYPS | 2.2;42 | SET |
|
193 | DATE OF CONCLUSIVE DX | 24;13 | FREE TEXT |
|
194 | MULT TUM RPT AS ONE PRIM | 24;14 | POINTER TO TYPE OF MULTIPLE TUMORS FILE (#169) | TYPE OF MULTIPLE TUMORS(#169)
|
195 | DATE OF MULTIPLE TUMORS | 24;15 | FREE TEXT |
|
196 | MULTIPLICITY COUNTER | 24;16 | FREE TEXT |
|
197 | EDITS CHECKSUM | EDITS;1 | FREE TEXT |
|
197.1 | CHECKSUM VERSION | EDITS;2 | FREE TEXT |
|
198 | DATE CASE LAST CHANGED | 7;21 | DATE |
|
199 | CASE LAST CHANGED BY | 7;22 | POINTER TO NEW PERSON FILE (#200) | NEW PERSON(#200)
|
200 | DATE LAST CONTACT | COMPUTED |
|
|
201 | SURVIVAL DAYS | COMPUTED |
|
|
202 | SURVIVAL MONTHS | COMPUTED |
|
|
203 | SURVIVAL (YEARS) | COMPUTED |
|
|
204 | WEEKS of FOLLOW-UP | COMPUTED |
|
|
205 | OVER-RIDE AGE/SITE/MORPH | OVRD;1 | SET |
|
206 | OVER-RIDE SEQNO/DXCONF | OVRD;2 | SET |
|
207 | OVER-RIDE SITE/LAT/SEQNO | OVRD;3 | SET |
|
208 | OVER-RIDE SURG/DXCONF | OVRD;4 | SET |
|
209 | OVER-RIDE SITE/TYPE | OVRD;5 | SET |
|
210 | OVER-RIDE HISTOLOGY | OVRD;6 | SET |
|
211 | OVER-RIDE REPORT SOURCE | OVRD;7 | SET |
|
212 | OVER-RIDE ILL-DEFINE SITE | OVRD;8 | SET |
|
213 | OVER-RIDE LEUK,LYMPHOMA | OVRD;9 | SET |
|
214 | OVER-RIDE SITE/BEHAVIOR | OVRD;10 | SET |
|
215 | OVER-RIDE SITE/EOD/DX DT | OVRD;11 | SET |
|
216 | OVER-RIDE SITE/LAT/EOD | OVRD;12 | SET |
|
217 | OVER-RIDE SITE/LAT/MORPH | OVRD;13 | SET |
|
218 | OVER-RIDE SS/NODESPOS | OVRD;14 | SET |
|
219 | OVER-RIDE SS/TNM-N | OVRD;15 | SET |
|
220 | OVER-RIDE SS/TNM-M | OVRD;16 | SET |
|
221 | OVER-RIDE SS/DISMET1 | OVRD;17 | SET |
|
222 | OVER-RIDE ACSN/CLASS/SEQ | OVRD;18 | SET |
|
223 | OVER-RIDE HOSPSEQ/DXCONF | OVRD;19 | SET |
|
224 | OVER-RIDE COC-SITE/TYPE | OVRD;20 | SET |
|
225 | OVER-RIDE HOSPSEQ/SITE | OVRD;21 | SET |
|
226 | OVER-RIDE SITE/TNM-STGGRP | OVRD;22 | SET |
|
227 | PERFORMANCE STATUS AT DX | 1;7 | SET |
|
228 | TREATMENT GUIDELINE #1 | 24;17 | SET |
|
229 | TREATMENT GUIDELINE #2 | 24;18 | SET |
|
230 | TREATMENT GUIDELINE #3 | 24;19 | SET |
|
231 | TREATMENT GUIDELINE LOCATION | 24;20 | FREE TEXT |
|
232 | TREATMENT GUIDELINE DOC DATE | 24;21 | DATE |
|
233 | INPATIENT STATUS | 2.3;3 | SET |
|
234 | RX HOSP--SURG APP 2010 | 2.3;4 | SET |
|
235 | TREATMENT STATUS | 2.3;5 | SET |
|
236 | DATE CASE INITIATED | 2.3;6 | DATE |
|
237 | FEE BASIS | 2.3;7 | SET |
|
237.1 | FEE BASIS LOCATION | 2.3;11 | FREE TEXT |
|
238 | OUTSIDE SLIDES REVIEWED | 2.3;8 | SET |
|
239 | MITOTIC RATE | 2.3;9 | SET |
|
240 | CS SCHEMA DISCRIMINATOR | CS3;1 | FREE TEXT |
|
241 | TNM CLIN DESCRIPTOR | 24;22 | SET |
|
242 | TNM PATH DESCRIPTOR | 24;23 | SET |
|
244 | INITIATED BY | 2.3;10 | POINTER TO NEW PERSON FILE (#200) | NEW PERSON(#200)
|
245 | NEOADJUVANT THERAPY (PRE-2021) | 3.1;40 | SET |
|
245.1 | NEOADJUVANT THERAPY | EOD;5 | SET |
|
245.2 | NEOADJUVANT THERAPY-CLIN RESP | EOD;6 | SET |
|
245.3 | NEOADJUVANT THERAPY-TX EFFECT | EOD;7 | NUMBER |
|
247 | CS REVIEW REQUIRED | CS3;2 | SET |
|
248 | NOTE TITLE | 25;1 | FREE TEXT |
|
249 | NOTE DATE | 25;2 | DATE |
|
250 | GLEASON SCORE (PATHOLOGIC) | 25;3 | FREE TEXT |
|
251 | NSLC STAGE 1-3 PATH LN STAGING | PM;1 | SET |
|
252 | REASON FOR NO LN BIOPSY | PM;2 | SET |
|
253 | DATE OF SURGERY CONSULT | PM;3 | DATE |
|
254 | INTENT OF SURGERY | PM;4 | SET |
|
255 | DATE ONCOLOGY CONSULT ORDERED | PM;5 | DATE |
|
256 | DATE ONCOLOGY CONSULT DONE | PM;6 | DATE |
|
257 | CHEMOTHERAPY RECOMMENDED | PM;7 | SET |
|
258 | INTENT OF CHEMOTHERAPY | PM;8 | SET |
|
259 | TYPE OF CHEMOTHERAPY | PM;9 | SET |
|
260 | REASON RADIATION STOPPED | PM;10 | SET |
|
261 | DOC FOR NO PLAT-BASED CHEMO | PM;11 | SET |
|
262 | MULTIMODALITY RADIATION TYPE | PM;12 | SET |
|
263 | REASON HORMONE THERAPY STOPPED | PM;28 | SET |
|
264 | DATE HOSPICE CONSULT INITIATED | PM;14 | DATE |
|
265 | DATE HOSPICE CONSULT COMPLETED | PM;15 | DATE |
|
266 | DATE HOSPICE CARE INITIATED | PM;16 | DATE |
|
267 | EGFR MUTATION TESTING | PM;17 | SET |
|
268 | EGFR MUTATION 1 | PM;18 | SET |
|
269 | EGFR MUTATION 2 | PM;19 | SET |
|
270 | PREOP OBSTRUCTING LESION | PM;13 | SET |
|
271 | ONCOLOGY REFERRAL | PM;20 | SET |
|
272 | DATE CHEMOTHERAPY RECOMMENDED | PM;21 | DATE |
|
273 | ANTI-EGFR MoAB THERAPY | PM;22 | SET |
|
274 | PERIRECTAL LN INVOLVEMENT | PM;23 | SET |
|
275 | RISK OF RECURRENCE | PM;24 | SET |
|
276 | ANDROGEN DEPRIVATION THERAPY | PM;25 | SET |
|
277 | DATE ADT INITIATED | PM;26 | DATE |
|
278 | NON-ADT CHEMOTHERAPY | PM;27 | SET |
|
279 | CLINICAL TRIALS DISCUSSION | 25;4 | SET |
|
280 | CLIN TNM DOCUMENTATION PRE-TX | 25;5 | SET |
|
280.1 | CL TNM DOCUMENTATION LOCATION | 25;7 | FREE TEXT |
|
280.2 | CL TNM DOCUMENTATION DATE | 25;8 | DATE |
|
281 | TX GUIDELINES DISCUSSION | 25;6 | SET |
|
282 | VACCR EXTRACT INDICATOR | EDITS;3 | SET |
|
283 | CS FIELD NEEDING REVIEW | CS3;3 | FREE TEXT |
|
284 | UDF1 | 25;9 | FREE TEXT |
|
284.1 | UDF2 | 25;10 | FREE TEXT |
|
284.2 | UDF3 | 25;11 | FREE TEXT |
|
284.3 | UDF4 | 25;12 | FREE TEXT |
|
284.4 | UDF5 | 25;13 | FREE TEXT |
|
284.5 | UDF6 | 25;14 | FREE TEXT |
|
284.6 | UDF7 | 25;15 | FREE TEXT |
|
284.7 | UDF8 | 25;16 | FREE TEXT |
|
284.8 | UDF9 | 25;17 | FREE TEXT |
|
284.9 | UDF10 | 25;18 | FREE TEXT |
|
285 | TEXT-STAGING | 22.1;0 | WORD-PROCESSING #165.5285 |
|
286 | TEXT-SITE SPECIFIC DATA ITEMS | 22.2;0 | WORD-PROCESSING #165.5286 |
|
287 | TEXT-COVID-19 | 22.3;0 | WORD-PROCESSING #165.5287 |
|
288 | TOBACCO USE SMOKING STATUS | 25;21 | SET |
|
289 | TEXT-HIV, SCA, DRUG & ETOH | 22.4;0 | WORD-PROCESSING #165.5289 |
|
300 | PATIENT REFERRED FOR TREATMENT | BLA1;1 | SET |
|
301 | LENGTH OF STAY | BLA1;2 | NUMBER |
|
302 | HISTORY OF CERVIX CA (PT) | BLA1;3 | SET |
|
303 | HISTORY OF COLON CA (PT) | BLA1;4 | SET |
|
304 | HISTORY OF BLADDER CA (PT) | BLA1;5 | SET |
|
305 | HISTORY OF HEAD & NECK CA (PT) | BLA1;6 | SET |
|
306 | HISTORY OF KIDNEY CA (PT) | BLA1;7 | SET |
|
307 | HISTORY OF PROSTATE CA (PT) | BLA1;8 | SET |
|
308 | HISTORY OF OTHER CA (PT) | BLA1;9 | SET |
|
309 | HISTORY OF BLADDER CA (FAM) | BLA1;10 | SET |
|
310 | HISTORY OF COLON CA (FAM) | BLA1;11 | SET |
|
311 | HISTORY OF LUNG CA (FAM) | BLA1;12 | SET |
|
312 | HISTORY OF PROSTATE CA (FAM) | BLA1;13 | SET |
|
313 | HISTORY OF OTHER CA (FAM) | BLA1;14 | SET |
|
314 | SMOKING HISTORY | BLA1;15 | NUMBER |
|
315 | DURATION OF SMOKING HISTORY | BLA1;16 | NUMBER |
|
316 | DURATION OF SMOKE FREE HISTORY | BLA1;17 | NUMBER |
|
317 | GROSS HEMATURIA | BLA1;18 | SET |
|
318 | MICROSCOPIC HEMATURIA | BLA1;19 | SET |
|
319 | URINARY FREQUENCY | BLA1;20 | SET |
|
320 | BLADDER IRRITABILITY | BLA1;21 | SET |
|
321 | DYSURIA | BLA1;22 | SET |
|
322 | OTHER CLINICAL DETECTIONS | BLA1;23 | SET |
|
323 | ONSET OF SYMPTOMS | BLA1;24 | DATE |
|
324 | DURATION OF GROSS HEMATURIA | BLA1;25 | NUMBER |
|
325 | DURATION OF DYSURIA | BLA1;26 | NUMBER |
|
326 | BIMANAUL EXAM OF BLADDER | BLA1;27 | SET |
|
327 | CYSTOSCOPY WITH BIOPSY | BLA1;28 | SET |
|
328 | CYSTOSCOPY WITHOUT BIOPSY | BLA1;29 | SET |
|
329 | FLOW CYTOMETRY | BLA1;30 | SET |
|
330 | INTRAVENOUS PYELOGRAM (BLA) | BLA1;31 | SET |
|
331 | URINE CYTOLOGY | BLA1;32 | SET |
|
332 | URINALYSIS | BLA1;33 | SET |
|
333 | OTHER DIAGNOSTIC PROCEDURES | BLA1;34 | SET |
|
334 | SPECIALTY MAKING DIAGNOSIS | BLA1;35 | SET |
|
335 | ABDOMINAL ULTRASOUND | BLA1;36 | SET |
|
336 | BONE IMAGING | BLA1;37 | SET |
|
337 | CHEST X-RAY (BLADDER) | BLA1;38 | SET |
|
338 | CT CHEST/LUNG | BLA1;39 | SET |
|
339 | CT ABDOMEN/PELVIS | BLA1;40 | SET |
|
340 | CT OTHER | BLA1;41 | SET |
|
341 | MRI PELVIS/ABDOMEN | BLA1;42 | SET |
|
342 | MRI OTHER | BLA1;43 | SET |
|
343 | OTHER STAGING PROCEDURES | BLA1;44 | SET |
|
344 | PRESENCE OF HYDRONEPHROSIS | BLA1;45 | SET |
|
345 | PRESENCE OF MULTIPLE TUMORS | BLA1;46 | SET |
|
346 | PROTOCOL ELIGIBILITY STATUS | BLA2;1 | SET |
|
347 | MANAGING PHYSICIAN (PRIMARY) | BLA2;2 | POINTER TO BLADDER PHYSICIAN SPECIALTY FILE (#166.12) | BLADDER PHYSICIAN SPECIALTY(#166.12)
|
348 | MANAGING PHYSICIAN (SECONDARY) | BLA2;3 | POINTER TO BLADDER PHYSICIAN SPECIALTY FILE (#166.12) | BLADDER PHYSICIAN SPECIALTY(#166.12)
|
349 | TUMOR RESECTION DURING TURB | BLA2;4 | SET |
|
350 | TYPE OF URINARY DIVERSION | BLA2;5 | SET |
|
351 | PELVIC LYMPH NODE DISSECT (BL) | BLA2;6 | SET |
|
352 | BLEEDING REQUIRING TRANSFUSION | BLA2;7 | SET |
|
353 | DEEP VENOUS THROMBOSIS | BLA2;8 | SET |
|
354 | MYOCARDIAL INFARCTION (MI) | BLA2;9 | SET |
|
355 | PELVIC ABSCESS | BLA2;10 | SET |
|
356 | PNEUMONIA REQ ANTIBIOTICS | BLA2;11 | SET |
|
357 | POST-OPERATIVE DEATH | BLA2;12 | SET |
|
358 | PULMONARY EMBOLISM/THROMBOSIS | BLA2;13 | SET |
|
359 | REOPERATION | BLA2;14 | SET |
|
360 | OTHER SURGICAL COMPLICATIONS | BLA2;15 | SET |
|
361 | DATE RADIATION ENDED | BLA2;16 | DATE |
|
362 | TOTAL RAD (cGy/rad) DOSE | BLA2;17 | NUMBER |
|
363 | REGIONAL TREATMENT MODALITY | BLA2;18 | POINTER TO REGIONAL TREATMENT MODALITY FILE (#166.13) | REGIONAL TREATMENT MODALITY(#166.13)
|
363.1 | BOOST TREATMENT MODALITY | 24;9 | POINTER TO REGIONAL TREATMENT MODALITY FILE (#166.13) | REGIONAL TREATMENT MODALITY(#166.13)
|
364 | URINARY INCONTINENCE | BLA2;19 | SET |
|
365 | HEMATURIA | BLA2;20 | SET |
|
366 | RADIATION BOWEL INJURY | BLA2;21 | SET |
|
367 | DATE CHEMOTHERAPY ENDED | BLA2;22 | DATE |
|
368 | ROUTE CHEMOTHERAPY ADMIN | BLA2;23 | SET |
|
369 | ADRIAMYCIN | BLA2;24 | SET |
|
370 | CARBOPLATINUM | BLA2;25 | SET |
|
371 | CISPLATIN | BLA2;26 | SET |
|
372 | CYCLOPHOSPHAMIDE | BLA2;27 | SET |
|
373 | 5-FLUOROURACIL | BLA2;28 | SET |
|
374 | GALLIUM NITRATE | BLA2;29 | SET |
|
375 | IFOSFAMIDE | BLA2;30 | SET |
|
376 | METHOTREXATE | BLA2;31 | SET |
|
377 | TAXOL | BLA2;32 | SET |
|
378 | THIOTEPA | BLA2;33 | SET |
|
379 | VINBLASTINE | BLA2;34 | SET |
|
380 | OTHER CHEMOTHERAPEUTIC AGENTS | BLA2;35 | SET |
|
381 | INDICATION FOR ADMIN OF AGENTS | BLA2;36 | SET |
|
382 | REASON CHEMOTHERAPY STOPPED | BLA2;41 | SET |
|
383 | BCG | BLA2;37 | SET |
|
384 | INTERFERON | BLA2;38 | SET |
|
385 | INTERLEUKIN-2 | BLA2;39 | SET |
|
386 | OTHER TYPE OF IMMUNOTHERAPY | BLA2;40 | SET |
|
387 | TYPE OF 1ST RECURRENCE/BLADDER | BLA2;42 | SET |
|
400 | HISTORY OF THYROID CA (FAM) | THY1;1 | SET |
|
401 | HISTORY OF LYMPHOMA (PT) | THY1;2 | SET |
|
402 | HISTORY OF CHILDHOOD MALIG | THY1;3 | SET |
|
403 | PRIOR EXPOSURE TO RADIATION | THY1;4 | SET |
|
404 | HISTORY OF GOITER (PT) | THY1;5 | SET |
|
405 | HISTORY OF GOITER (FAM) | THY1;6 | SET |
|
406 | HISTORY OF GRAVES DISEASE (PT) | THY1;7 | SET |
|
407 | HISTORY OF THYROIDITIS (PT) | THY1;8 | SET |
|
408 | DYSPHAGIA | THY1;9 | SET |
|
409 | HOARSENESS OR VOICE CHANGE | THY1;10 | SET |
|
410 | NECK NODAL MASS | THY1;11 | SET |
|
411 | PAIN, BONE | THY1;12 | SET |
|
412 | PAIN, NECK | THY1;13 | SET |
|
413 | PATHOLOGIC FRACTURE | THY1;14 | SET |
|
414 | STRIDOR/DIFFICULTY BREATHING | THY1;15 | SET |
|
415 | THYROID MASS | THY1;16 | SET |
|
416 | WEIGHT LOSS | THY1;17 | SET |
|
417 | OTHER SIGNS/SYMPTOMS | THY1;18 | SET |
|
418 | BONE SCAN (THYROID) | THY1;19 | SET |
|
419 | CHEST X-RAY (THYROID) | THY1;20 | SET |
|
420 | CT SCAN OF NECK (THYROID) | THY1;21 | SET |
|
421 | CT SCAN OF CHEST | THY1;22 | SET |
|
422 | INCISIONAL BIOPSY OF THYROID | THY1;23 | SET |
|
423 | LARYNGOSCOPY | THY1;24 | SET |
|
424 | NECK X-RAY (AP & LATERAL) | THY1;25 | SET |
|
425 | NEEDLE ASPIRATION OF NECK NODE | THY1;26 | SET |
|
426 | NEEDLE ASPIRATION OF THYROID | THY1;27 | SET |
|
427 | MRI OF NECK | THY1;28 | SET |
|
428 | THYROID SCAN | THY1;29 | SET |
|
429 | ULTRASOUND OF THYROID | THY1;30 | SET |
|
430 | OTHER DIAGNOSTIC/SURGICAL TEST | THY1;31 | SET |
|
431 | BLOOD VESSEL INVASION | THY1;32 | SET |
|
432 | EXTRA-THYROIDAL EXTENSION | THY1;33 | SET |
|
433 | MULTIFOCAL | THY1;34 | SET |
|
434 | LOCATION OF POSITIVE NODES | THY1;35 | SET |
|
435 | DATE MOST DEFINITIVE SURG DIS | THY1;36 | DATE |
|
436 | AIRWAY PROBLEM | THY1;37 | SET |
|
437 | BLEEDING/HEMATOMA | THY1;38 | SET |
|
438 | HYPOCALCEMIA | THY1;39 | SET |
|
439 | RECURRENT NERVE INJURY | THY1;40 | SET |
|
440 | WOUND INFECTION | THY1;41 | SET |
|
441 | POSTOPERATIVE DEATH | THY1;42 | SET |
|
442 | REGIONAL DOSE: cGy | THY1;43 | NUMBER |
|
443 | BOOST DOSE: cGy | THY1;44 | NUMBER |
|
444 | INITIAL DOSE OF RADIOIODINE | THY1;45 | NUMBER |
|
445 | SECOND DOSE OF RADIOIODINE | THY1;46 | NUMBER |
|
446 | ADJUVANT CHEMOTHERAPY (THY) | THY1;47 | SET |
|
500 | HISTORY OF SOFT TIS SARC (FAM) | STS1;1 | SET |
|
501 | HISTORY OF ANY CANCER (PT) | STS1;2 | SET |
|
502 | ANGIOGRAM OF PRIMARY | STS1;3 | SET |
|
503 | BONE MARROW ASPIRATE OR BIOPSY | STS1;4 | SET |
|
504 | BONE SCAN (SOFT TIS SARCOMA) | STS1;5 | SET |
|
505 | CHEST X-RAY (STS/NHL) | STS1;6 | SET |
|
506 | CT SCAN OF CHEST (STS) | STS1;7 | SET |
|
507 | CT SCAN OF PRIMARY | STS1;8 | SET |
|
508 | LIVER FUNCTION STUDIES (STS) | STS1;9 | SET |
|
509 | LYMPHANGIOGRAM | STS1;10 | SET |
|
510 | MRI OF PRIMARY | STS1;11 | SET |
|
511 | MRI OF OTHER | STS1;12 | SET |
|
512 | SKELETAL X-RAY | STS1;13 | SET |
|
513 | SONOGRAM | STS1;14 | SET |
|
514 | CYTOGENETICS | STS1;15 | SET |
|
515 | ELECTRON MICROSCOPY | STS1;16 | SET |
|
516 | IMMUNOHISTOCHEMISTRY | STS1;17 | SET |
|
517 | IN SITU HYBRIDIZATION | STS1;18 | SET |
|
518 | OUTSIDE CONFIRMATION REQUESTED | STS1;19 | SET |
|
519 | SUBSITE | STS1;20 | POINTER TO ONCOLOGY SUBSITE FILE (#166.3) | ONCOLOGY SUBSITE(#166.3)
|
520 | TYPE OF ADDITIONAL CODING SYS | STS1;21 | SET |
|
521 | VALUE OF ADDITIONAL CODING SYS | STS1;22 | SET |
|
522 | PATHOLOGIC SIZE OF TUMOR | STS1;23 | NUMBER |
|
523 | DEPTH OF TUMOR | STS1;24 | SET |
|
524 | CONSULTATIONS (MED ONCOLOGIST) | STS1;25 | SET |
|
525 | CONSULTATIONS (RAD ONCOLOGIST) | STS1;26 | SET |
|
526 | TREATING SURGEON | STS2;1 | SET |
|
527 | ASA CLASS | STS2;2 | SET |
|
528 | FINE NEEDLE ASPIRATION | STS1;27 | NUMBER |
|
529 | CORE NEEDLE BIOPSY | STS1;28 | NUMBER |
|
530 | INCISIONAL BIOPSY (STS PCE) | STS1;29 | NUMBER |
|
531 | EXCISIONAL BIOPSY | STS1;30 | NUMBER |
|
532 | EXTERNAL BEAM RADIATION | STS2;3 | SET |
|
533 | EXTERNAL BEAM RAD FRACTIONS | STS2;4 | NUMBER |
|
534 | EXTERNAL BEAM RADIATION ENERGY | STS2;5 | NUMBER |
|
535 | INTRAOPERATIVE RADIATION | STS2;6 | SET |
|
536 | INTRAOPERATIVE RADIATION DOSE | STS2;7 | NUMBER |
|
537 | INTRAOPERATIVE RADIATION ENER | STS2;8 | NUMBER |
|
538 | BRACHYTHERAPY | STS2;9 | SET |
|
539 | BRACHYTHERAPY DAYS | STS2;10 | NUMBER |
|
540 | BRACHYTHERAPY RADIATION DOSE | STS2;11 | NUMBER |
|
541 | DATE BRACHYTHERAPY STARTED | STS2;12 | DATE |
|
542 | DATE BRACHYTHERAPY ENDED | STS2;13 | DATE |
|
543 | CYTOXAN | STS2;14 | SET |
|
544 | DTIC | STS2;15 | SET |
|
545 | DOXORUBICIN (STS) | STS2;16 | SET |
|
546 | ETOPOSIDE | STS2;17 | SET |
|
547 | CISPLATIN METHOD OF DELIVERY | STS2;18 | SET |
|
548 | CYTOXAN METHOD OF DELIVERY | STS2;19 | SET |
|
549 | DTIC METHOD OF DELIVERY | STS2;20 | SET |
|
550 | DOXORUBICIN METHOD OF DELIVERY | STS2;21 | SET |
|
551 | ETOPOSIDE METHOD OF DELIVERY | STS2;22 | SET |
|
552 | IFOSFAMIDE METHOD OF DELIVERY | STS2;23 | SET |
|
553 | CISPLATIN LOCATION | STS2;24 | SET |
|
554 | CYTOXAN LOCATION | STS2;25 | SET |
|
555 | DTIC LOCATION | STS2;26 | SET |
|
556 | DOXORUBICIN LOCATION | STS2;27 | SET |
|
557 | ETOPOSIDE LOCATION | STS2;28 | SET |
|
558 | IFOSFAMIDE LOCATION | STS2;29 | SET |
|
559 | COLONY STIMULATING FACTORS | STS2;30 | SET |
|
560 | PROTOCOL PARTICIPATION | STS2;31 | SET |
|
561 | OTHER PROTOCOL | STS2;32 | SET |
|
562 | REFERRED TO REHAB SERVICES | STS2;33 | SET |
|
563 | PHYSICAL THERAPY/REHABILTATION | STS2;34 | SET |
|
564 | TRANSFERRED TO REHABILITATION | STS2;35 | SET |
|
565 | NUMBER OF HOSPITALIZATIONS | STS2;36 | NUMBER |
|
566 | TOTAL LENGTH OF STAYS | STS2;37 | NUMBER |
|
567 | DATE EXT BEAM RAD STARTED | STS2;38 | DATE |
|
600 | CLINICAL DX WITH BONE LESION | PRO1;1 | SET |
|
601 | CLINICAL DX BY RECTAL EXAM | PRO1;2 | SET |
|
602 | CYTOLOGY | PRO1;3 | SET |
|
603 | INCIDENTAL FINDING IN TURP | PRO1;4 | SET |
|
604 | NEEDLE ASPIRATION BIOPSY | PRO1;5 | SET |
|
605 | NEEDLE BIOPSY, NOS | PRO1;6 | SET |
|
606 | PERINEAL BIOPSY | PRO1;7 | SET |
|
607 | TRANSRECTAL BIOPSY | PRO1;8 | SET |
|
608 | TRUS | PRO1;9 | SET |
|
609 | TRANSURETHRAL RESECTION | PRO1;10 | SET |
|
610 | OTHER METHOD OF DX (PROSTATE) | PRO1;11 | SET |
|
611 | BONE MARROW ASPIRATION | PRO1;12 | SET |
|
612 | BONE SCAN (PROSTATE) | PRO1;13 | SET |
|
613 | BONE X-RAY | PRO1;14 | SET |
|
614 | CHEST X-RAY (PROSTATE) | PRO1;15 | SET |
|
615 | CT SCAN OF PRIMARY SITE | PRO1;16 | SET |
|
616 | INTRAVENOUS PYELOGRAM (PRO) | PRO1;17 | SET |
|
617 | LIVER SCAN | PRO1;18 | SET |
|
618 | MRI (PRO) | PRO1;19 | SET |
|
619 | PELVIC LYMPH NODE DISSECT (PR) | PRO1;20 | SET |
|
620 | PROSTATIC ACID PHOSPHATASE | PRO1;21 | SET |
|
621 | PROSTATE SPECIFIC ANTIGEN | PRO1;22 | SET |
|
622 | OTHER DIAGNOSTIC INFORMATION | PRO1;23 | SET |
|
623 | GLEASON SCORE (CLINICAL) | PRO1;24 | FREE TEXT |
|
623.1 | PREDOMINANT PATTERN (02-40) | PRO2;43 | NUMBER |
|
623.2 | LESSER PATTERN (02-40) | PRO2;44 | NUMBER |
|
623.3 | GLEASON'S SCORE (50-70) | PRO2;45 | FREE TEXT |
|
623.4 | PREDOMINANT PATTERN (50-70) | PRO2;46 | NUMBER |
|
623.5 | LESSER PATTERN (50-70) | PRO2;47 | NUMBER |
|
624 | RESEARCH PROTOCOL | PRO1;25 | SET |
|
625 | RAD THERAPY PLANNED/GIVEN | PRO1;26 | SET |
|
626 | INTERSTITIAL RAD PLANNED/GIVEN | PRO1;27 | SET |
|
627 | IODINE 125 | PRO1;28 | SET |
|
628 | GOLD 198 | PRO1;29 | SET |
|
629 | PALLADIUM 103 | PRO1;30 | SET |
|
630 | IRIDIUM 192 | PRO1;31 | SET |
|
631 | OTHER INTERSTITIAL, NOS | PRO1;32 | SET |
|
632 | EXTERNAL RAD PLANNED/GIVEN | PRO1;33 | SET |
|
633 | PROSTATE REGION ONLY | PRO1;34 | SET |
|
634 | PROSTATE AND PELVIC NODES | PRO1;35 | SET |
|
635 | PROSTATE & PELVIC PARA-AORTIC | PRO1;36 | SET |
|
636 | DISTANT METASTATIC SITES | PRO1;37 | SET |
|
637 | OTHER EXTERNAL SITES, NOS | PRO1;38 | SET |
|
638 | TOTAL RAD DOSE (PROSTATE) | PRO1;39 | SET |
|
639 | TOTAL RAD DOSE (PELVIC NODES) | PRO1;40 | SET |
|
640 | TOTAL RAD DOSE (PARA-AORTIC) | PRO1;41 | SET |
|
641 | RESEARCH PROTOCOL (RADIATION) | PRO1;42 | SET |
|
642 | HORMONE THERAPY PLANNED/GIVEN | PRO1;43 | SET |
|
643 | ESTROGENS | PRO1;44 | SET |
|
644 | ANTIANDROGENS | PRO1;45 | SET |
|
645 | PROGESTATIONAL AGENTS | PRO1;46 | SET |
|
646 | LUTEINIZING HORMONES | PRO1;47 | SET |
|
647 | ORCHIECTOMY | PRO1;48 | SET |
|
648 | OTHER EXOGENOUS HORMONE AGENTS | PRO1;49 | SET |
|
649 | BACKACHE (1ST RECURRENCE) | PRO1;50 | SET |
|
650 | BONE SCAN (1ST RECURRENCE) | PRO1;51 | SET |
|
651 | LETHARGY | PRO1;52 | SET |
|
652 | RECTAL EXAM (1ST RECURRENCE) | PRO1;53 | SET |
|
653 | TUMOR MARKER (1ST RECURRENCE) | PRO1;54 | SET |
|
654 | WEIGHT LOSS (1ST RECURRENCE) | PRO1;55 | SET |
|
655 | OTHER METHODS (1ST RECURRENCE) | PRO1;56 | SET |
|
656 | REASON FOR 2ND COURSE | PRO1;57 | SET |
|
657 | FAM HIST OF PROSTATE CA (PR98) | PRO2;1 | SET |
|
658 | HEMATURIA (PR98) | PRO2;2 | SET |
|
659 | LOWER BACK PAIN (PR98) | PRO2;3 | SET |
|
660 | TROUBLE URINATING (PR98) | PRO2;4 | SET |
|
661 | CLIN DX W/ BONE LESION (PR98) | PRO2;5 | SET |
|
662 | CLIN DX BY RECTAL EXAM (PR98) | PRO2;6 | SET |
|
663 | CYTOLOGY (PR98) | PRO2;7 | SET |
|
664 | DIGITAL TRANSRECTAL BIO (PR98) | PRO2;8 | SET |
|
665 | INCIDENTAL FIND IN TURP (PR98) | PRO2;9 | SET |
|
666 | NEEDLE BIOPSY, NOS (PR98) | PRO2;10 | SET |
|
667 | PERINEAL BIOPSY (PR98) | PRO2;11 | SET |
|
668 | PSA METHOD OF DIAGNOSIS (PR98) | PRO2;12 | SET |
|
669 | TRANSRECTAL BIOPSY (PR98) | PRO2;13 | SET |
|
670 | TRANSURETHRAL RESECTION (PR98) | PRO2;14 | SET |
|
671 | BONE MARROW ASPIRATION (PR98) | PRO2;15 | SET |
|
672 | BONE SCAN (PR98) | PRO2;16 | SET |
|
673 | BONE X-RAY (PR98) | PRO2;17 | SET |
|
674 | CHEST X-RAY (PR98) | PRO2;18 | SET |
|
675 | CT SCAN OF ABDOMEN (PR98) | PRO2;19 | SET |
|
676 | CT SCAN OF PELVIS (PR98) | PRO2;20 | SET |
|
677 | INTRAVENOUS PYELOGRAM (PR98) | PRO2;21 | SET |
|
678 | MRI (PR98) | PRO2;22 | SET |
|
679 | PELVIC LYMPH ND DISSECT (PR98) | PRO2;23 | SET |
|
680 | POLYMERASE CHAIN REACT (PR98) | PRO2;24 | SET |
|
681 | PROSTATIC ACID PHOSPH (PR98) | PRO2;25 | SET |
|
682 | PSA DIAGNOSTIC EVAL (PR98) | PRO2;26 | SET |
|
683 | ULTRASOUND OF ABDOMEN (PR98) | PRO2;27 | SET |
|
684 | PSA | PRO2;28 | FREE TEXT |
|
685 | WATCHFUL WAITING (PR98) | PRO2;29 | SET |
|
686 | LENGTH OF STAY (PR98) | PRO2;30 | NUMBER |
|
687 | LAPAROSCOPIC (PR98) | PRO2;31 | SET |
|
688 | OPEN (PR98) | PRO2;32 | SET |
|
689 | PERMANENT RECTAL INJURY (PR98) | PRO2;33 | SET |
|
690 | THROMBOEMBOLISM (PR98) | PRO2;34 | SET |
|
691 | URETHRAL STRICTURE (PR98) | PRO2;35 | SET |
|
692 | RADIATION FACILITY | PRO2;36 | SET |
|
693 | ROUTE OF INTERSTITIAL RAD | PRO2;37 | SET |
|
694 | TYPE OF RADIATION ADMIN | PRO2;38 | SET |
|
695 | GASTROINTESTINAL COMPLICATIONS | PRO2;39 | SET |
|
696 | GASTROURINARY COMPLICATIONS | PRO2;40 | SET |
|
697 | ANORECTAL COMPLICATIONS | PRO2;41 | SET |
|
698 | CHRONIC COMPLICATIONS | PRO2;42 | SET |
|
699 | URETHRAL/BLADDER COMPLICATIONS | PRO2;48 | SET |
|
699.1 | DATE OF ORCHIECTOMY | PRO2;49 | DATE |
|
700 | HISTORY OF COLORECTAL CA (FAM) | COL1;1 | SET |
|
701 | HISTORY OF COLORECTAL CA (PT) | COL1;2 | SET |
|
702 | MULTIPLE COLORECTAL PRIMARIES | COL1;3 | SET |
|
703 | HISTORY OF BREAST CA (PT) | COL1;4 | SET |
|
704 | HISTORY OF LUNG CA (PT) | COL1;5 | SET |
|
705 | HISTORY OF OVARIAN CA (PT) | COL1;6 | SET |
|
706 | HISTORY OF OVARIAN CARCINOMA | COL1;7 | SET |
|
707 | HISTORY OF STOMACH CA (PT) | COL1;8 | SET |
|
708 | HISTORY OF THYROID CA (PT) | COL1;9 | SET |
|
709 | HISTORY OF UTERUS CA (PT) | COL1;10 | SET |
|
710 | PREVIOUS TAH/BSO | COL1;11 | SET |
|
711 | FAMILIAL ADENOMATOUS POLYPS | COL1;12 | SET |
|
712 | HNPCC | COL1;13 | SET |
|
713 | INFLAMMATORY BOWEL DISEASE | COL1;14 | SET |
|
714 | PRIOR POLYPS | COL1;15 | SET |
|
715 | POLYPS | COL1;16 | NUMBER |
|
716 | DURATION OF ANEMIA | COL1;17 | NUMBER |
|
717 | DURATION OF BOWEL OBSTRUCTION | COL1;18 | NUMBER |
|
718 | DURATION OF BOWEL HABIT CHANGE | COL1;19 | NUMBER |
|
719 | DURATION OF EMERGENCY PRES-OBS | COL1;20 | NUMBER |
|
720 | DURATION OF JAUNDICE | COL1;21 | NUMBER |
|
721 | DURATION OF MALAISE | COL1;22 | NUMBER |
|
722 | DURATION OF BLOOD IN STOOL | COL1;23 | NUMBER |
|
723 | DURATION OF PAIN (ABDOMINAL) | COL1;24 | NUMBER |
|
724 | DURATION OF PAIN (PELVIC) | COL1;25 | NUMBER |
|
725 | DURATION OF RECTAL BLEEDING | COL1;26 | NUMBER |
|
726 | DURATION OF OTHER | COL1;27 | NUMBER |
|
727 | ENDOSCOPIC METHOD | COL1;28 | SET |
|
728 | RADIOGRAPHIC METHOD | COL1;29 | SET |
|
729 | SCREENING DIGITAL RECTAL EXAM | COL1;30 | SET |
|
730 | SCREENING PHYSICAL EXAM METHOD | COL1;31 | SET |
|
731 | OTHER INITIAL METHOD | COL1;32 | SET |
|
732 | REASON LEADING TO EVENTUAL DX | COL1;33 | SET |
|
733 | BARIUM ENEMA, DOUBLE CONTRAST | COL1;34 | SET |
|
734 | BARIUM ENEMA, SINGLE CONTRAST | COL1;35 | SET |
|
735 | BARIUM ENEMA, NOS | COL1;36 | SET |
|
736 | BIOPSY OF PRIMARY SITE | COL1;37 | SET |
|
737 | BIOPSY OF METASTATIC SITE | COL1;38 | SET |
|
738 | CT SCAN OF LIVER | COL1;39 | SET |
|
739 | CT SCAN OF PRIMARY SITE (COL) | COL1;40 | SET |
|
740 | CARCINOEMBRYONIC ANTIGEN (CEA) | COL1;41 | SET |
|
741 | CHEST ROENTGENOGRAM | COL1;42 | SET |
|
742 | COLONOSCOPY | COL1;43 | SET |
|
743 | DIGITAL RECTAL EXAM | COL1;44 | SET |
|
744 | FLEXIBLE SIGMOIDOSCOPY | COL1;45 | SET |
|
745 | INTRAVENOUS PYELOGRAM (COL) | COL1;46 | SET |
|
746 | SERUM-LIVER FUNCTION TEST | COL1;47 | SET |
|
747 | MRI (COL) | COL1;48 | SET |
|
748 | PROCTOSCOPY (RIGID) | COL1;49 | SET |
|
749 | STOOL GUAIAC (OCCULT BLOOD) | COL1;50 | SET |
|
750 | ULTRASOUND, LIVER, ABDOMEN | COL1;51 | SET |
|
751 | ULTRASOUND, ENDORECTAL | COL1;52 | SET |
|
752 | TUMOR LEVEL-ENDOSCOPIC EXAM | COL2;1 | NUMBER |
|
753 | LEVEL OF RECTAL TUMOR | COL2;2 | SET |
|
754 | PROXIMAL MARGIN OF RESECTION | COL2;3 | SET |
|
755 | DISTAL MARGIN OF RESECTION | COL2;4 | SET |
|
756 | RADIAL MARGIN OF RESECTION | COL2;5 | SET |
|
757 | DIST TO CLOSEST MUCOSAL MARGIN | COL2;6 | NUMBER |
|
758 | DIST TO CLOSEST RADIAL MARGIN | COL2;7 | NUMBER |
|
759 | BLOOD VESSEL OR LYMPHATIC INV | COL2;8 | SET |
|
760 | EXTRAMURAL VENOUS INVASION | COL2;9 | SET |
|
761 | PROMINENT LYMPHOID INFILTRATE | COL2;10 | SET |
|
762 | PHYS PROVIDING DEF TREATMENT | COL2;11 | SET |
|
763 | ADDITIONAL SURGICAL PROCEDURES | COL2;12 | NUMBER |
|
764 | LAPAROSCOPY USED DURING CDS | COL2;13 | SET |
|
765 | METHOD OF ANASTOMOSIS | COL2;14 | SET |
|
766 | CM FROM ANASTOMOSIS TO DENTATE | COL2;15 | NUMBER |
|
767 | COLOSTOMY | COL2;16 | SET |
|
768 | OOPHORECTOMY | COL2;17 | SET |
|
769 | PATHOLOGICAL STATUS | COL2;18 | SET |
|
770 | ABDOMINAL INFECTION | COL2;19 | SET |
|
771 | ABSCESS | COL2;20 | SET |
|
772 | ADMISSION FOR NEUTROPENIA | COL2;21 | SET |
|
773 | ANASTOMOTIC DEHISCENCE | COL2;22 | SET |
|
774 | DEHYDRATION | COL2;23 | SET |
|
775 | DIARRHEA | COL2;24 | SET |
|
776 | EARLY BOWEL OBSTRUCTION | COL2;25 | SET |
|
777 | PERINEAL INFECTION | COL2;26 | SET |
|
778 | PNEUMONIA (COL) | COL2;27 | SET |
|
779 | PROCTITIS | COL2;28 | SET |
|
780 | PULMONARY EMBOLISM (COL) | COL2;29 | SET |
|
781 | RADIATION ENTERITIS | COL2;30 | SET |
|
782 | STOMA COMPLICATION | COL2;31 | SET |
|
783 | URINARY TRACT INFECTION | COL2;32 | SET |
|
784 | ENDOCAVITARY RADIATION (ECRT) | COL2;33 | SET |
|
785 | INTRA-OPERATIVE RAD THERAPY | COL2;34 | SET |
|
786 | PRIMARY TUMOR RAD DOSE (cGy) | COL2;35 | NUMBER |
|
787 | NUMBER OF RADIATION TREATMENTS | COL2;36 | NUMBER |
|
788 | ADJUVANT CHEMOTHERAPY (COL) | COL2;37 | SET |
|
789 | 5 FU (FLUOROURACIL) | COL2;38 | SET |
|
790 | LEUCOVORIN | COL2;39 | SET |
|
791 | LEVAMISOLE | COL2;40 | SET |
|
792 | CPT 11 | COL2;41 | SET |
|
793 | OTHER ADJUVANT THERAPY | COL2;42 | SET |
|
794 | DURATION OF ADJUVANT THERAPY | COL2;43 | SET |
|
795 | COMPLETED DURATION OF THERAPY | COL2;44 | SET |
|
796 | NUTRITIONAL CONSULTATION | COL2;45 | SET |
|
797 | OCCUPATIONAL THERAPY | COL2;46 | SET |
|
798 | OSTOMY CONSULTATION | COL2;47 | SET |
|
799 | PSYCHOSOCIAL | COL2;48 | SET |
|
800 | HISTORY OF LEUKEMIA (FAM) | NHL1;1 | SET |
|
801 | HISTORY OF NON-HODGKIN'S LYMPH | NHL1;2 | SET |
|
802 | HISTORY OF HODGKIN'S LYMPHOMA | NHL1;3 | SET |
|
803 | 1ST PRIMARY SITE | NHL1;4 | POINTER TO ICDO TOPOGRAPHY FILE (#164) | ICDO TOPOGRAPHY(#164)
|
804 | 1ST PRIMARY HISTOLOGY | NHL1;5 | POINTER TO ICD-O-2 MORPHOLOGY FILE (#164.1) | ICD-O-2 MORPHOLOGY(#164.1)
|
805 | 2ND PRIMARY SITE | NHL1;6 | POINTER TO ICDO TOPOGRAPHY FILE (#164) | ICDO TOPOGRAPHY(#164)
|
806 | 2ND PRIMARY HISTOLOGY | NHL1;7 | POINTER TO ICD-O-2 MORPHOLOGY FILE (#164.1) | ICD-O-2 MORPHOLOGY(#164.1)
|
807 | ORGAN TRANSPLANT | NHL1;8 | SET |
|
808 | HIV POSITIVE | NHL1;9 | SET |
|
809 | CROHN'S DISEASE | NHL1;10 | SET |
|
810 | HASHIMOTO'S THYROIDITIS | NHL1;11 | SET |
|
811 | SYSTEMIC LUPUS ERYTHEMATOSUS | NHL1;12 | SET |
|
812 | RHEUMATOID ARTHRITIS | NHL1;13 | SET |
|
813 | PNEUMOCYSTIS CARINII | NHL1;14 | SET |
|
814 | CMV INFECTION | NHL1;15 | SET |
|
815 | TUBERCULOSIS | NHL1;16 | SET |
|
816 | MYCOBACTERIUM AVIUM | NHL1;17 | SET |
|
817 | OTHER PARASITIC INFECTIONS | NHL1;18 | SET |
|
818 | OTHER CONGENITAL DISEASES | NHL1;19 | SET |
|
819 | OPPORTUNISTIC DISEASE | NHL1;20 | SET |
|
820 | PREVIOUS CHEMOTHERAPY | NHL1;21 | SET |
|
821 | PREVIOUS RADIATION THERAPY | NHL1;22 | SET |
|
822 | AIDS RISK CATEGORY | NHL1;23 | NUMBER |
|
823 | CT SCAN OF BRAIN | NHL1;24 | SET |
|
824 | CT SCAN OF ABDOMEN/PELVIS | NHL1;25 | SET |
|
825 | MRI OF BRAIN | NHL1;26 | SET |
|
826 | MRI OF CHEST | NHL1;27 | SET |
|
827 | MRI OF ABDOMEN/PELVIS | NHL1;28 | SET |
|
828 | GALLIUM SCAN | NHL1;29 | SET |
|
829 | PET SCAN | NHL1;30 | SET |
|
830 | LUMBAR PUNCTURE | NHL1;31 | SET |
|
831 | HEMOGLOBIN/HEMATOCRIT | NHL1;32 | SET |
|
832 | WHITE COUNT | NHL1;33 | SET |
|
833 | PLATELET COUNT | NHL1;34 | SET |
|
834 | LACTIC DEHYDROGENASE (LDH) | NHL1;35 | SET |
|
835 | LIVER FUNCTION STUDIES (NHL) | NHL1;36 | SET |
|
836 | TOTAL PROTEIN/ALBUMIN | NHL1;37 | SET |
|
837 | GENE REARRANGEMENTS | NHL1;38 | SET |
|
838 | REVIEW OF PATHOLOGY/OTHER INST | NHL1;39 | SET |
|
839 | LYMPH NODE BIOPSY | NHL1;40 | SET |
|
840 | BONE MARROW BIOPSY | NHL1;41 | SET |
|
841 | CSF CYTOLOGY | NHL1;42 | SET |
|
842 | OTHER SITE BIOPSY | NHL1;43 | SET |
|
843 | SYSTEMIC SYMPTOMS | NHL1;44 | SET |
|
844 | CD4 COUNT | NHL1;45 | SET |
|
845 | HIV VIRAL LOADS | NHL1;46 | SET |
|
846 | SPECIFIC HISTOLOGIC INFO | NHL2;1 | SET |
|
847 | CELL TYPE OF LYMPHOMA | NHL2;2 | SET |
|
848 | PATIENT STATUS AT DIAGNOSIS | NHL2;3 | SET |
|
849 | TYPE OF STAGING SYSTEM (PED) | NHL2;4 | POINTER TO TYPE OF STAGING SYSTEM (PEDIATRIC) FILE (#164.6) | TYPE OF STAGING SYSTEM (PEDIATRIC)(#164.6)
|
850 | PEDIATRIC STAGE | NHL2;5 | FREE TEXT |
|
851 | STAGED BY (PEDIATRIC STAGE) | NHL2;6 | SET |
|
852 | EXTRANODAL SITE 1 | NHL2;7 | FREE TEXT |
|
853 | EXTRANODAL SITE 2 | NHL2;8 | FREE TEXT |
|
854 | EXTRANODAL SITE 3 | NHL2;9 | FREE TEXT |
|
855 | EXTRANODAL SITE W/C-D SURGERY | NHL2;10 | FREE TEXT |
|
856 | EXTRANODAL SITE SURGICAL PROC | NHL2;11 | NUMBER |
|
857 | LYMPH NODES ABOVE DIAPHRAGM | NHL2;12 | SET |
|
858 | LYMPH NODES BELOW DIAPHRAGM | NHL2;13 | SET |
|
859 | BRAIN | NHL2;14 | SET |
|
860 | OTHER EXTRANODAL SITE(S) | NHL2;15 | SET |
|
861 | TOTAL BODY | NHL2;16 | SET |
|
862 | RADIATION/CHEMO SEQUENCE | NHL2;17 | NUMBER |
|
863 | PROTOCOL | NHL2;18 | SET |
|
864 | SYSTEMIC CHEMOTHERAPY | NHL2;19 | SET |
|
865 | SYSTEMIC CHEMOTHERAPY DATE | NHL2;20 | DATE |
|
866 | SYSTEMIC CHEMOTHERAPY CYCLES | NHL2;21 | NUMBER |
|
867 | CHLORAMBUCIL | NHL2;22 | SET |
|
868 | CYCLOPHOSPHAMIDE (NHL) | NHL2;23 | SET |
|
869 | DOXORUBICIN (NHL) | NHL2;24 | SET |
|
870 | FLUDARABINE | NHL2;25 | SET |
|
871 | CHOP | NHL2;26 | SET |
|
872 | CVP | NHL2;27 | SET |
|
873 | COMLA | NHL2;28 | SET |
|
874 | MACOP-B | NHL2;29 | SET |
|
875 | M-BACOD | NHL2;30 | SET |
|
876 | PRO-MACE-Cyta BOM | NHL2;31 | SET |
|
877 | OTHER SYSTEMIC CHEMO AGENTS | NHL2;32 | SET |
|
878 | HIGH DOSE SYSTEMIC CHEMO | NHL2;33 | SET |
|
879 | INTRATHECAL CHEMOTHERAPY | NHL2;34 | SET |
|
880 | PURPOSE OF INTRATHECAL CHEMO | NHL2;35 | SET |
|
881 | INTERFERON (NHL) | NHL2;36 | SET |
|
882 | INTERLEUKIN-2 (IL-2) (NHL) | NHL2;37 | SET |
|
883 | MONOCLONAL ANTIBODIES | NHL2;38 | SET |
|
884 | VACCINE THERAPY | NHL2;39 | SET |
|
900 | DAUGHTER (BR98) | BRE1;1 | SET |
|
901 | MATERNAL AUNT (BR98) | BRE1;2 | SET |
|
902 | MATERNAL GRANDMOTHER (BR98) | BRE1;3 | SET |
|
903 | MOTHER (BR98) | BRE1;4 | SET |
|
904 | ONE SISTER (BR98) | BRE1;5 | SET |
|
905 | MORE THAN ONE SISTER (BR98) | BRE1;6 | SET |
|
906 | FATHER (BR98) | BRE1;7 | SET |
|
907 | BROTHER (BR98) | BRE1;8 | SET |
|
908 | FAM HISTORY BREAST CA (BR98) | BRE1;9 | SET |
|
909 | HISTORY OF BREAST CA (BR98) | BRE1;10 | SET |
|
910 | SYNCHRONOUS BREAST CA (BR98) | BRE1;11 | SET |
|
911 | COLON (BR98) | BRE1;12 | SET |
|
912 | OVARY (BR98) | BRE1;13 | SET |
|
913 | UTERUS (BR98) | BRE1;14 | SET |
|
914 | PROSTATE (BR98) | BRE1;15 | SET |
|
915 | OTHER (BR98) | BRE1;16 | SET |
|
916 | HORMONE REPLACEMENT TPY (BR98) | BRE1;17 | SET |
|
917 | HORMONE REPLACEMENT YRS (BR98) | BRE1;18 | SET |
|
918 | UNKNOWN MAMMOGRAM (BR98) | BRE1;19 | SET |
|
919 | UNKNOWN MAMMOGRAM DT (BR98) | BRE1;20 | DATE |
|
920 | SCREENING MAMMOGRAM (BR98) | BRE1;21 | SET |
|
921 | SCREENING MAMMOGRAM DT (BR98) | BRE1;22 | DATE |
|
922 | DIAGNOSTIC MAMMOGRAM (BR98) | BRE1;23 | SET |
|
923 | DIAGNOSTIC MAMMOGRAM DT (BR98) | BRE1;24 | DATE |
|
924 | MAGNIFICATION MAMMOGRAM (BR98) | BRE1;25 | SET |
|
925 | MAGNIFICATION MAMM DT (BR98) | BRE1;26 | DATE |
|
926 | MAMMOGRAM (BR98) | BRE1;27 | SET |
|
927 | ULTRASOUND (BR98) | BRE1;28 | SET |
|
928 | MOST DEFINITIVE MAMM (BR98) | BRE1;29 | SET |
|
929 | DATE OF PATHOLOGIC DX (BR98) | BRE1;30 | DATE |
|
930 | DCSI ALSO PRESENT (BR98) | BRE1;31 | FREE TEXT |
|
931 | ARCHITECTURE PATTERN (BR98) | BRE1;32 | SET |
|
932 | NUCLEAR GRADE (BR98) | BRE1;33 | SET |
|
933 | SKIN INVOLVEMENT (BR98) | BRE1;34 | SET |
|
934 | CHEST WALL INVOLVEMENT (BR98) | BRE1;35 | SET |
|
935 | PECTORAL INVOLVEMENT (BR98) | BRE1;36 | SET |
|
936 | DERMAL/LYMPHATIC INV (BR98) | BRE1;37 | SET |
|
937 | DNA INDEX/PLOIDY (BR98) | BRE1;38 | SET |
|
940 | ANDROGEN RECEPTOR (BR98) | BRE1;41 | SET |
|
941 | TYPE OF TEST (BR98) | BRE1;42 | SET |
|
942 | SIZE OF DCIS TUMOR (MM) (BR98) | BRE1;43 | NUMBER |
|
943 | SENTINEL NODE BIOPSY | BRE1;44 | SET |
|
944 | SENTINEL NODES EXAMINED (BR98) | BRE1;45 | SET |
|
945 | SENTINEL NODES POSITIVE (BR98) | BRE1;46 | SET |
|
946 | SENTINEL NODES DETECTED (BR98) | BRE1;47 | SET |
|
947 | SPECIMEN RADIOGRAPH (BR98) | BRE1;48 | SET |
|
948 | SUBMITTED TO PATHOLOGY (BR98) | BRE1;49 | SET |
|
949 | MARGIN DISTANCE (BR98) | BRE1;50 | SET |
|
950 | RE-EXCISION (BR98) | BRE1;51 | SET |
|
951 | MICROSCOPIC STATUS (BR98) | BRE1;52 | SET |
|
952 | PRE-RADIATION MAMMOGRAM (BR98) | BRE1;53 | SET |
|
953 | SITES IRRADIATED (BR98) | BRE1;54 | SET |
|
954 | cGy DOSE TO BREAST (BR98) | BRE1;55 | NUMBER |
|
955 | SPECIFIC HORMONE THPY (BR98) | BRE1;56 | SET |
|
956 | CHEMOTHERAPY REGIME (BR98) | BRE1;57 | SET |
|
993 | REGIONAL TX MODALITY CONV FLAG | 27;7 | SET |
|
994 | TYPE OF FIRST RECUR CONV FLAG | 27;6 | SET |
|
995 | STAGED BY CONV FLAG | 27;5 | SET |
|
996 | SURGICAL MARGINS CONV FLAG | 27;2 | SET |
|
997 | STAGE FLAG | 27;1 | SET |
|
998 | SCOPE OF LN SURGERY CONV FLAG | 27;3 | SET |
|
999 | SURGICAL PROC/OTHER CONV FLAG | 27;4 | SET |
|
999.1 | DATE OF DIAGNOSIS FLAG | 27;8 | NUMBER |
|
999.11 | RX DATE SURG DISCH FLAG | 27;17 | NUMBER |
|
999.12 | RX DATE-RADIATION FLAG | 27;18 | NUMBER |
|
999.13 | RX DATE RAD ENDED FLAG | 27;19 | NUMBER |
|
999.14 | RX DATE SYSTEMIC FLAG | 27;20 | NUMBER |
|
999.15 | RX DATE-CHEMO FLAG | 27;21 | NUMBER |
|
999.16 | RX DATE-HORMONE FLAG | 27;22 | NUMBER |
|
999.17 | RX DATE-BRM FLAG | 27;23 | NUMBER |
|
999.18 | RX DATE-OTHER FLAG | 27;24 | NUMBER |
|
999.19 | RX DATE-DX/STG PROC FLAG | 27;25 | NUMBER |
|
999.2 | DATE CONCLUSIVE DX FLAG | 27;9 | NUMBER |
|
999.21 | RECURRENCE DATE-1ST FLAG | 27;26 | NUMBER |
|
999.22 | DATE OF LAST CONTACT FLAG | 27;27 | NUMBER |
|
999.23 | SUBSQ RX 2ND CRS DATE FLAG | 27;28 | NUMBER |
|
999.24 | SUBSQ RX 3RD CRS DATE FLAG | 27;29 | NUMBER |
|
999.25 | SUBSQ RX 4TH CRS DATE FLAG | 27;30 | NUMBER |
|
999.26 | ADDRESS AT DX--STATE | 27;31 | FREE TEXT |
|
999.27 | ADDRESS AT DX--COUNTRY | 27;32 | FREE TEXT |
|
999.28 | ADDRESS CURRENT--STATE | 27;33 | FREE TEXT |
|
999.289 | ADDRESS CURRENT--POSTAL CODE | 27;35 | FREE TEXT |
|
999.29 | ADDRESS CURRENT--COUNTRY | 27;34 | FREE TEXT |
|
999.3 | DATE OF MULT TUMORS FLAG | 27;10 | NUMBER |
|
999.4 | DATE OF FIRST CONTACT FLAG | 27;11 | NUMBER |
|
999.5 | DATE OF INPT ADM FLAG |